F. Touret

Genomic surveillance reveals that the dengue 2 virus lineage responsible for the 2023-2024 epidemic in the French Caribbean Islands is resistant to Mosnodenvir

The paper identifies a mutation in dengue virus genomes from the 2023-2024 French Caribbean epidemic that confers resistance to the anti-dengue compound mosnodenvir.

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

The paper generates and evaluates SARS-CoV-2 mutants resistant to protease inhibitors nirmatrelvir and ensitrelvir, showing in vitro and in vivo resistance and linking M49L mutation prevalence to Xocova(R) use.

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model

This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model

This study evaluates Sotrovimab's antiviral activity against BQ.1.1 and XBB.1 Omicron variants in a hamster model, finding retained but reduced efficacy compared to earlier variants.

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 Omicron sub-lineages

This study evaluates the neutralizing activity of monoclonal antibodies against SARS-CoV-2 Omicron sub-lineages and finds reduced efficacy against several variants.

Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals

This paper identifies biosynthetic proteins (Reps) that bind the SARS-CoV-2 spike RBD and neutralize the virus, including variants, with high potency and stability.

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

The paper evaluates the neutralizing activity of eight therapeutic antibodies against an Omicron SARS-CoV-2 isolate and finds significant loss of efficacy for most, with only Sotrovimab showing minimal reduction.

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant

This study shows niclosamide is effective against SARS-CoV-2 and its variants in a human airway model, supporting its potential as a COVID-19 therapy.

Alpha variant versus D614G strain in the Syrian hamster model

This study compares the SARS-CoV-2 Alpha variant and G614 strain in Syrian hamsters, finding similar replication and disease outcomes but a slight fitness advantage for G614.

Replicative fitness SARS-CoV-2 20I/501Y.V1 variant in a human reconstituted bronchial epithelium

This study compares the replication efficiency of the SARS-CoV-2 20I/501Y.V1 variant with an ancestral strain in human bronchial epithelium models, finding the variant outcompetes the ancestral strain in competition experiments.

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.

Evaluation of heating and chemical protocols for inactivating SARS-CoV-2

The paper evaluates heating and chemical protocols for inactivating SARS-CoV-2, finding that Triton-X100 in guanidinium thiocyanate buffers achieves 6-log reduction, while heating protocols affect RNA detection.

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase

This study shows Favipiravir inhibits SARS-CoV-2 by targeting its RNA polymerase through chain termination, slowed synthesis, and mutagenesis.

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

This study screens an FDA-approved chemical library to identify potential inhibitors of SARS-CoV-2 replication in vitro, finding several compounds with antiviral potency.

Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery

This paper establishes a dengue virus panel representing all genotypes to aid in antiviral drug discovery, showing varying compound efficacies across genotypes.

Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone

This paper develops a chimeric Zika virus vaccine using a yellow fever 17-D backbone and shows it induces neutralizing antibodies and protects mice against ZIKV challenge.